• Over 100 new Physical Therapy (PT) sites signed during the quarter
• Cash receipts from customers increased to $280k (up from $185k in Q1 FY26)
• Secured exclusive Neuromorphic Process-In-Memory (PIM) IP from Technion

Dorsavi Ltd (ASX:DVL) released its Quarterly Activities Report and Quarterly Cashflow Report for the quarter ended 31 December 2025. The company reported significant commercial momentum in the US Physical Therapy (PT) market, onboarding over 100 new sites during the quarter. This growth reflects the successful execution of the first quarter of the five-year sales agreement with Select Medical, one of the largest PT networks in the US, alongside adoption by other major PT groups and elite sporting organizations. Dorsavi's 'high-touch' engagement model, utilizing face-to-face training sessions, has proven highly effective at accelerating product adoption and clinical integration. The company also reported a 50% increase in cash receipts from customers to $280k in Q2 FY26, compared to $185k in the prior quarter. During the quarter, Dorsavi completed a significant leadership transition, with Mathew Regan commencing as Group Chief Executive Officer on November 1, 2025, to lead the company's strategic shift toward higher-value, technology-led growth opportunities. The company also reached critical milestones in its proprietary Resistive Random Access Memory (RRAM) development, with plans to scale from the 40nm to the 22nm technology node. Additionally, Dorsavi transformed its technological foundation through the exclusive acquisition of a breakthrough neuromorphic portfolio from the Technion - Israel Institute of Technology, elevating its platforms into a new era of hardware-native intelligence. This strategic integration of RRAM technology, neuromorphic processing-in-memory, and adaptive interface technology represents a fundamental shift in Dorsavi's value proposition, enabling the company to participate in the emerging field of Generative Computing at the edge.